Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: GlobalData
|
$250.00
|
|
Provider: Wright Reports
|
$460.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Precision System Science Co., Ltd. Lowers Consolidated Mid-year and Full-year Outlook for FY 2012
Precision System Science Co., Ltd. announced that it has lowered its consolidated mid-year outlook for revenue from JPY 1,960 million to JPY 1,722 million, operating profit from JPY 20 million to a loss of JPY 49 million, ordinary profit from JPY 15 million to a loss of JPY 79 million, net profit from JPY 5 million to a loss of JPY 95 million and earning per share from JPY 54.79 to a loss of JPY 1,040.98, for the fiscal year ending June 2012. In addition, the Company has also lowered its consolidated full-year outlook for revenue from JPY 4,000 million to JPY 3,620 million, operating profit from JPY 40 million to JPY 10 million, ordinary profit from JPY 30 million to a loss of JPY 30 million, net profit from JPY 10 million to a loss of JPY 60 million and earning per share from JPY 109.58 to a loss of JPY 657.46, for the fiscal year ending June 2012. This is due to the decreased sales as well as the impact of the higher yen, among others.
Latest Developments for Precision System Science Co Ltd
- Precision System Science Co Ltd Lowers Consolidated Mid-year and Amends Full-year Outlook for FY 2013
- Precision System Science Co., Ltd. Lowers Consolidated Full-year Outlook for FY 2012
- Precision System Science Co., Ltd. Acquires NPS co.,LTD.
- Precision System Science Co., Ltd. Lowers Consolidated Full-year Outlook for FY 2011
Latest Key Developments in Advanced
- Covidien PLC Approves Separation Of Pharmaceuticals Business And Declares Dividend Of Mallinckrodt Ordinary Shares
- Nephros Inc Announces Completion Of Rights Offering
- Volcano Corp Announces Preliminary Results From ADVISE II Study
- Nordion Inc Enters Into Agreement To Divest Targeted Therapies Business To BTG Plc
- Share this
- Link this
- Digg this


Follow Reuters